--- title: "Capricor 治疗公司因第四季度亏损幅度超出预期而股价下跌" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/279082570.md" description: "Capricor Therapeutics 的股价下跌 8.6%，至 30.54 美元，此前报告第四季度亏损 3020 万美元，远超分析师预期的 50 万美元收入和每股亏损 51 美分。该公司在本季度没有产生任何收入，较去年同期的 1110 万美元下降。Capricor 正在等待 FDA 对 Deramiocel 治疗杜氏肌营养不良症的批准，预计将在 2026 年 8 月 22 日之前收到回复" datetime: "2026-03-13T19:05:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279082570.md) - [en](https://longbridge.com/en/news/279082570.md) - [zh-HK](https://longbridge.com/zh-HK/news/279082570.md) --- # Capricor 治疗公司因第四季度亏损幅度超出预期而股价下跌 By Elias Schisgall Shares of Capricor Therapeutics fell after the company posted a wider-than-expected loss in the fourth quarter after not bringing in any revenue. Shares were down 8.6% to $30.54 in Friday afternoon trading. The stock has more than doubled in value in the past year. The biotechnology company on Thursday posted a quarterly loss of $30.2 million, or 62 cents a share, compared with a loss of $7.12 million, or 16 cents a share, a year earlier. Capricor did not post any revenue during the quarter, compared with $11.1 million a year prior. The company said its primary sources of revenue were $40 million in upfront and first-development milestone payments and $10 million in second-development milestone payments per the company's distribution agreement with Nippon Shinyaku. Those payments were recognized as of year-end 2024, it said. Analysts surveyed by FactSet were expecting $500,000 in revenue and a loss of 51 cents a share. The company said it is continuing to work toward approval for Deramiocel to treat Duchenne muscular dystrophy. A biologics license application for the treatment is under review by the Food and Drug Administration, and the company expects a response from the agency by Aug. 22. Write to Elias Schisgall at elias.schisgall@wsj.com (END) Dow Jones Newswires March 13, 2026 14:48 ET (18:48 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. ### 相关股票 - [IXJ.US](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [CAPR.US](https://longbridge.com/zh-CN/quote/CAPR.US.md) - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) - [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md) - [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [VHT.US](https://longbridge.com/zh-CN/quote/VHT.US.md) - [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md) - [XLV.US](https://longbridge.com/zh-CN/quote/XLV.US.md) - [IHE.US](https://longbridge.com/zh-CN/quote/IHE.US.md) - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md) - [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) ## 相关资讯与研究 - [减肥药公司 Kailera TherapeuticsIPO 定价 14-16 美元/股 拟周五登陆纳斯达克](https://longbridge.com/zh-CN/news/282645838.md) - [诺和诺德携手 OpenAI 加速药物研发 旨在提升效率](https://longbridge.com/zh-CN/news/282699021.md) - [挪威主权财富基金称无意减持美国资产，仍将一半投资配置于美国](https://longbridge.com/zh-CN/news/282909039.md) - [东方证券：全球首个 pan-RAS 药物数据惊艳 突破胰腺癌治疗困局](https://longbridge.com/zh-CN/news/282928576.md) - [强生公司销售额增长近 10%，上调 2026 年业绩展望](https://longbridge.com/zh-CN/news/282850988.md)